Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DALGAN vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of moderate to severe pain (FDA-approved),Preoperative analgesia,Postoperative pain relief,Adjunct to anesthesia
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation and N-demethylation. Involves UDP-glucuronosyltransferase (UGT) enzymes and possibly cytochrome P450 (CYP) 3A4 contributes to minor metabolism to inactive metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~20% bound to albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3–5 L/kg; suggests extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 40–60% (first-pass metabolism); IM: ~70%; rectal: ~50%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 10-50 m L/min: administer 50-75% of usual dose every 8-12 hours. GFR <10 m L/min: administer 50% of usual dose every 12 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and extend interval to every 8-12 hours. Child-Pugh C: reduce dose by 75% and extend interval to every 12 hours.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 4 mg/kg/day. IV: 0.3-0.5 mg/kg every 6 hours; maximum 2 mg/kg/day.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at 50% of adult dose; titrate slowly to response; maximum 300 mg/day. Avoid in patients with creatinine clearance <30 m L/min.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Dalgan exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression: monitor closely, especially during initiation or dose escalation,Opioid-induced hyperalgesia: paradoxical increase in pain sensitivity,Adrenal insufficiency: monitor for symptoms of hypocortisolism,Severe hypotension: risk in hypovolemic patients or those with compromised blood pressure,Seizures: may exacerbate seizure disorders,Risks of use in patients with head injury or increased intracranial pressure,Avoid abrupt discontinuation: taper dose to prevent withdrawal syndrome,May precipitate withdrawal in opioid-dependent patients due to antagonist activity at mu receptors
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to dezocine or any component of the formulation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid grapefruit juice as it may increase dezocine levels via CYP3A4 inhibition. No other significant food interactions reported; take with or without food. Limit alcohol to prevent additive CNS depression.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal syndrome if prolonged use near term. Avoid unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted in breast milk; M/P ratio not established. Limited human data; potential for infant sedation and withdrawal. Use only if essential, monitor infant for drowsiness and poor feeding.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No standard dose adjustments; pharmacokinetic changes (increased clearance, volume of distribution) may require higher doses to maintain efficacy. Use lowest effective dose; avoid in first trimester if possible. Taper to prevent withdrawal.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Dalgan (dezocine) is a mixed agonist-antagonist opioid with ceiling effect for respiratory depression; use caution in opioid-tolerant patients due to risk of precipitating withdrawal. Not recommended for prolonged use due to potential for dependence. Monitor for hypotension and bradycardia, especially in elderly or volume-depleted patients.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not consume alcohol or other central nervous system depressants while taking this drug.,Report any signs of withdrawal (e.g., anxiety, sweating, cramping) or allergic reaction (rash, difficulty breathing) immediately.,Store at room temperature away from moisture and heat; keep out of reach of children.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DALGAN vs ABSTRAL, answered by our medical review team.
DALGAN is a Opioid Analgesic that works by Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DALGAN and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DALGAN is: Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DALGAN and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DALGAN is classified as Category C. FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.